Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Alessandro Broccoli, Beatrice Casadei, Alice Morigi, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, Francesco Pisani, Michele Merli, Carlo Visco, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, Stefano Molica, Fiorella IlariucciGian Matteo Rigolin, Francesco D'Alò, Anna Vanazzi, Elisa Santambrogio, Roberto Marasca, Lucia Mastrullo, Claudia Castellino, Giovanni Desabbata, Ilaria Scortechini, Livio Trentin, Lucia Morello, Lisa Argnani, Pier Luigi Zinzani

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive disease, hardly curable with standard chemo-immunotherapy. Current approaches have greatly improved patients' outcomes, nevertheless the disease is still characterized by high relapse rates. Before approval by EMA, Italian patients with relapsed/refractory MCL were granted ibrutinib early access through a Named Patient Program (NPP). An observational, retrospective, multicenter study was conducted. Seventyseven heavily pretreated patients were enrolled. At the end of therapy there were 14 complete responses and 14 partial responses, leading to an overall response rate of 36.4%. At 40 months overall survival was 37.8% and progression free survival was 30%; disease free survival was 78.6% at 4 years: 11/14 patients are in continuous complete response with a median of 36 months of follow up. Hematological toxicities were manageable, and main extra-hematological toxicities were diarrhea (9.4%) and lung infections (9.0%). Overall, 4 (5.2%) atrial fibrillations and 3 (3.9%) hemorrhagic syndromes occurred. In conclusions, thrombocytopenia, diarrhea and lung infections are the relevant adverse events to be clinically focused on; regarding effectiveness, ibrutinib is confirmed to be a valid option for refractory/relapsed MCL also in a clinical setting mimicking the real world.

Original languageEnglish
Pages (from-to)23443-23450
Number of pages8
JournalOncotarget
Volume9
Issue number34
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Mantle-Cell Lymphoma
Life Change Events
Observational Studies
Disease-Free Survival
Diarrhea
Lung
Infection
Thrombocytopenia
Immunotherapy
Atrial Fibrillation
Multicenter Studies
Lymphoma
Retrospective Studies
PCI 32765
Recurrence
Survival

Keywords

  • Ibrutinib
  • Mantle cell lymphoma
  • Real life
  • Refractory
  • Relapsed

ASJC Scopus subject areas

  • Oncology

Cite this

Italian real life experience with ibrutinib : Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. / Broccoli, Alessandro; Casadei, Beatrice; Morigi, Alice; Sottotetti, Federico; Gotti, Manuel; Spina, Michele; Volpetti, Stefano; Ferrero, Simone; Spina, Francesco; Pisani, Francesco; Merli, Michele; Visco, Carlo; Paolini, Rossella; Zilioli, Vittorio Ruggero; Baldini, Luca; Di Renzo, Nicola; Tosi, Patrizia; Cascavilla, Nicola; Molica, Stefano; Ilariucci, Fiorella; Rigolin, Gian Matteo; D'Alò, Francesco; Vanazzi, Anna; Santambrogio, Elisa; Marasca, Roberto; Mastrullo, Lucia; Castellino, Claudia; Desabbata, Giovanni; Scortechini, Ilaria; Trentin, Livio; Morello, Lucia; Argnani, Lisa; Zinzani, Pier Luigi.

In: Oncotarget, Vol. 9, No. 34, 01.05.2018, p. 23443-23450.

Research output: Contribution to journalArticle

Broccoli, A, Casadei, B, Morigi, A, Sottotetti, F, Gotti, M, Spina, M, Volpetti, S, Ferrero, S, Spina, F, Pisani, F, Merli, M, Visco, C, Paolini, R, Zilioli, VR, Baldini, L, Di Renzo, N, Tosi, P, Cascavilla, N, Molica, S, Ilariucci, F, Rigolin, GM, D'Alò, F, Vanazzi, A, Santambrogio, E, Marasca, R, Mastrullo, L, Castellino, C, Desabbata, G, Scortechini, I, Trentin, L, Morello, L, Argnani, L & Zinzani, PL 2018, 'Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma', Oncotarget, vol. 9, no. 34, pp. 23443-23450. https://doi.org/10.18632/oncotarget.25215
Broccoli, Alessandro ; Casadei, Beatrice ; Morigi, Alice ; Sottotetti, Federico ; Gotti, Manuel ; Spina, Michele ; Volpetti, Stefano ; Ferrero, Simone ; Spina, Francesco ; Pisani, Francesco ; Merli, Michele ; Visco, Carlo ; Paolini, Rossella ; Zilioli, Vittorio Ruggero ; Baldini, Luca ; Di Renzo, Nicola ; Tosi, Patrizia ; Cascavilla, Nicola ; Molica, Stefano ; Ilariucci, Fiorella ; Rigolin, Gian Matteo ; D'Alò, Francesco ; Vanazzi, Anna ; Santambrogio, Elisa ; Marasca, Roberto ; Mastrullo, Lucia ; Castellino, Claudia ; Desabbata, Giovanni ; Scortechini, Ilaria ; Trentin, Livio ; Morello, Lucia ; Argnani, Lisa ; Zinzani, Pier Luigi. / Italian real life experience with ibrutinib : Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. In: Oncotarget. 2018 ; Vol. 9, No. 34. pp. 23443-23450.
@article{53e95d3fa71e4574b816d50ae64102a6,
title = "Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma",
abstract = "Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive disease, hardly curable with standard chemo-immunotherapy. Current approaches have greatly improved patients' outcomes, nevertheless the disease is still characterized by high relapse rates. Before approval by EMA, Italian patients with relapsed/refractory MCL were granted ibrutinib early access through a Named Patient Program (NPP). An observational, retrospective, multicenter study was conducted. Seventyseven heavily pretreated patients were enrolled. At the end of therapy there were 14 complete responses and 14 partial responses, leading to an overall response rate of 36.4{\%}. At 40 months overall survival was 37.8{\%} and progression free survival was 30{\%}; disease free survival was 78.6{\%} at 4 years: 11/14 patients are in continuous complete response with a median of 36 months of follow up. Hematological toxicities were manageable, and main extra-hematological toxicities were diarrhea (9.4{\%}) and lung infections (9.0{\%}). Overall, 4 (5.2{\%}) atrial fibrillations and 3 (3.9{\%}) hemorrhagic syndromes occurred. In conclusions, thrombocytopenia, diarrhea and lung infections are the relevant adverse events to be clinically focused on; regarding effectiveness, ibrutinib is confirmed to be a valid option for refractory/relapsed MCL also in a clinical setting mimicking the real world.",
keywords = "Ibrutinib, Mantle cell lymphoma, Real life, Refractory, Relapsed",
author = "Alessandro Broccoli and Beatrice Casadei and Alice Morigi and Federico Sottotetti and Manuel Gotti and Michele Spina and Stefano Volpetti and Simone Ferrero and Francesco Spina and Francesco Pisani and Michele Merli and Carlo Visco and Rossella Paolini and Zilioli, {Vittorio Ruggero} and Luca Baldini and {Di Renzo}, Nicola and Patrizia Tosi and Nicola Cascavilla and Stefano Molica and Fiorella Ilariucci and Rigolin, {Gian Matteo} and Francesco D'Al{\`o} and Anna Vanazzi and Elisa Santambrogio and Roberto Marasca and Lucia Mastrullo and Claudia Castellino and Giovanni Desabbata and Ilaria Scortechini and Livio Trentin and Lucia Morello and Lisa Argnani and Zinzani, {Pier Luigi}",
year = "2018",
month = "5",
day = "1",
doi = "10.18632/oncotarget.25215",
language = "English",
volume = "9",
pages = "23443--23450",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "34",

}

TY - JOUR

T1 - Italian real life experience with ibrutinib

T2 - Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

AU - Broccoli, Alessandro

AU - Casadei, Beatrice

AU - Morigi, Alice

AU - Sottotetti, Federico

AU - Gotti, Manuel

AU - Spina, Michele

AU - Volpetti, Stefano

AU - Ferrero, Simone

AU - Spina, Francesco

AU - Pisani, Francesco

AU - Merli, Michele

AU - Visco, Carlo

AU - Paolini, Rossella

AU - Zilioli, Vittorio Ruggero

AU - Baldini, Luca

AU - Di Renzo, Nicola

AU - Tosi, Patrizia

AU - Cascavilla, Nicola

AU - Molica, Stefano

AU - Ilariucci, Fiorella

AU - Rigolin, Gian Matteo

AU - D'Alò, Francesco

AU - Vanazzi, Anna

AU - Santambrogio, Elisa

AU - Marasca, Roberto

AU - Mastrullo, Lucia

AU - Castellino, Claudia

AU - Desabbata, Giovanni

AU - Scortechini, Ilaria

AU - Trentin, Livio

AU - Morello, Lucia

AU - Argnani, Lisa

AU - Zinzani, Pier Luigi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive disease, hardly curable with standard chemo-immunotherapy. Current approaches have greatly improved patients' outcomes, nevertheless the disease is still characterized by high relapse rates. Before approval by EMA, Italian patients with relapsed/refractory MCL were granted ibrutinib early access through a Named Patient Program (NPP). An observational, retrospective, multicenter study was conducted. Seventyseven heavily pretreated patients were enrolled. At the end of therapy there were 14 complete responses and 14 partial responses, leading to an overall response rate of 36.4%. At 40 months overall survival was 37.8% and progression free survival was 30%; disease free survival was 78.6% at 4 years: 11/14 patients are in continuous complete response with a median of 36 months of follow up. Hematological toxicities were manageable, and main extra-hematological toxicities were diarrhea (9.4%) and lung infections (9.0%). Overall, 4 (5.2%) atrial fibrillations and 3 (3.9%) hemorrhagic syndromes occurred. In conclusions, thrombocytopenia, diarrhea and lung infections are the relevant adverse events to be clinically focused on; regarding effectiveness, ibrutinib is confirmed to be a valid option for refractory/relapsed MCL also in a clinical setting mimicking the real world.

AB - Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma (MCL) is an aggressive disease, hardly curable with standard chemo-immunotherapy. Current approaches have greatly improved patients' outcomes, nevertheless the disease is still characterized by high relapse rates. Before approval by EMA, Italian patients with relapsed/refractory MCL were granted ibrutinib early access through a Named Patient Program (NPP). An observational, retrospective, multicenter study was conducted. Seventyseven heavily pretreated patients were enrolled. At the end of therapy there were 14 complete responses and 14 partial responses, leading to an overall response rate of 36.4%. At 40 months overall survival was 37.8% and progression free survival was 30%; disease free survival was 78.6% at 4 years: 11/14 patients are in continuous complete response with a median of 36 months of follow up. Hematological toxicities were manageable, and main extra-hematological toxicities were diarrhea (9.4%) and lung infections (9.0%). Overall, 4 (5.2%) atrial fibrillations and 3 (3.9%) hemorrhagic syndromes occurred. In conclusions, thrombocytopenia, diarrhea and lung infections are the relevant adverse events to be clinically focused on; regarding effectiveness, ibrutinib is confirmed to be a valid option for refractory/relapsed MCL also in a clinical setting mimicking the real world.

KW - Ibrutinib

KW - Mantle cell lymphoma

KW - Real life

KW - Refractory

KW - Relapsed

UR - http://www.scopus.com/inward/record.url?scp=85046713776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046713776&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25215

DO - 10.18632/oncotarget.25215

M3 - Article

AN - SCOPUS:85046713776

VL - 9

SP - 23443

EP - 23450

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 34

ER -